Taken together, the findings provide new evidence that histone arginine methylation modification regulates protein synthesis in LSCs and highlight PRMT1 as a valuable druggable target for patients with CML. The gene discussed is PRMT1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.